Showing 4571-4580 of 8849 results for "".
- High Kissability Marks for Restylane Kysse in New Phase 4 Studyhttps://practicaldermatology.com/news/high-kissability-marks-for-restylane-kysse-in-new-phase-4-study/2460465/In a recent first-of-its-kind phase IV, Kissability study for an injectable hyaluronic acid (HA) lip filler, subject satisfaction as well as partner satisfaction were evaluated following treatment with Restylane Kysse. Many consumers report they often keep their lip treatments a
- Leo Pharma: FDA Accepts BLA for Tralokinumab for ADhttps://practicaldermatology.com/news/leo-pharma-fda-accepts-bla-for-tralokinumab-for-ad/2460462/The FDA has accepted the Biologics License Application (BLA) for Leo Pharma’s tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD), the company says. A taget action date has been set in the second quarter of 2021. Tralokinumab is a fully human mo
- Aerolase Appoints Industry Vet Didier Leclercq to Leadership Teamhttps://practicaldermatology.com/news/aerolase-appoints-industry-vet-didier-leclercq-to-leadership-team/2460448/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med once it was acquired by G
- Ortho Dermatologics Launches Arazlo Lotion in the UShttps://practicaldermatology.com/news/ortho-dermatologics-launches-arazlo-lotion-in-the-us/2460447/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics launched Arazlo (tazarotene) Lotion, 0.045%. Now available commercially to health care professionals in the US, it was FDA approved in December 2019 as the first tazaroten
- Late-Breaking Data: Skyrizi Achieves Superior Rates of Complete Skin Clearance for Psoriasis Compared to Secukinumab at 52 Weekshttps://practicaldermatology.com/news/late-breaking-data-show-skyrizi-achieves-superior-rates-of-complete-skin-clearance-for-psoriasis-compared-to-secukinumab-at-52-weeks/2460423/New late-breaking Phase 3b head-to-head data show superior rates of skin clearance for AbbVie's risankizumab-rzaa (Skyrizi) compared to secukinumab (Cosentyx) at week 52. Sixty-six percent of psoriasis patients receiving Skyrizi achieved completely clear skin—100 percent clearance in th
- Sciton Unveils mJOULE Platform Featuring BBL HERO And MOXIhttps://practicaldermatology.com/news/sciton-unveils-mjoule-platform-featuring-bbl-hero-and-moxi/2460420/Sciton Inc. is rolling out their mJOULE dual-wavelength platform which includes a new fractional treatment, MOXI, and BBL HERO. MOXI delivers non-ablative laser energy to revitalize skin and BroadBand Light HERO (High Energy Rapid Output) allows practitioners to treat the entire body wi
- Dermavant Completes Enrollment for Long-Term Safety Study of Tapinarof in Adult Psoriasishttps://practicaldermatology.com/news/dermavant-completes-enrollment-for-long-term-safety-study-of-tapinarof-in-adult-psoriasis/2460416/Patient enrollment in Dermavant’s long-term safety study of tapinarof is now complete, the company says. Tapinarof is a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) being investigated for use in adult patients diagnosed with plaq
- New from Obagi: Two Sunscreens and a Hydrating Serumhttps://practicaldermatology.com/news/new-from-obagi-two-sunscreens-and-a-hydrating-serum/2460415/Obagi is launching two new Physical Defense Sunscreens and Daily Hydro-Drops. The new SUZANOBAGIMD Physical Defense Sunscreens, available in broad-spectrum SPF 40 and tinted SPF 50, defend against five light sources, including high energy visible light, or blue light, visible light
- Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4’s Role in HS and ADhttps://practicaldermatology.com/news/kymera-therapeutics-initiates-enrollment-in-non-interventional-trial-evaluating-irak4s-role-in-hs-and-ad/2460411/Kymera Therapeutics Inc. has started enrollment in a non-interventional trial evaluating IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). Kymera is developing a selective orally administered IRAK4 degraders for the treatment of toll-like
- Cynosure Rolls Out Elite iQ Aesthetic Workstation For Laser Hair Removal, Skin Revitalizationhttps://practicaldermatology.com/news/cynosure-rolls-out-elite-iq-aesthetic-workstation-for-laser-hair-removal-skin-revitalization/2460407/